Autologous Cell Therapy Market Research Report Information by Therapy (Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies), By Application (Cancer, Cardiology, Urology, Neurovascular, Gastrointestinal, General Surgery, Pain Management & Trauma), By Source (Bone Marrow, Epidermis, Others), By End-User (Hospitals & Clinics, Ambulatory Centers), and By Region (North America, Europe, Asia Pacific, Rest of the World) - Market Forecast Till 2032

Global Autologous Cell Therapy Market Overview

The Autologous Cell Therapy Market Size was valued at USD 5.27 billion in 2022 and is projected to grow from USD 5.38 Billion in 2023 to USD 30.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.56% during the forecast period (2023 - 2032). The market of Autologous Cell Therapy is experiencing robust growth driven by factors such as increasing awareness about personalized medical treatments, advancements in regenerative medicine, and growing applications in various medical fields. This market is witnessing significant investments in research and development, leading to the emergence of novel therapies and technologies. The rising prevalence of chronic diseases and the potential for improved patient outcomes are propelling the demand for autologous cell therapies worldwide.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Global Expansion, Pharmicell is focusing on expanding its market presence for Cellgram, an autologous stem cell therapy for cardiovascular conditions

Autologous Cell Therapy Market Trends

• Increasing awareness about personalized medical treatments boosts market growth.

The autologous cell therapy market is experiencing remarkable growth, propelled by the surging awareness and adoption of personalized medical treatments. This innovative approach, which harnesses a patient's own cells for therapeutic purposes, has gained significant traction within the field of regenerative medicine. The primary driving force behind this expansion is the growing recognition among healthcare professionals and patients alike of the immense advantages offered by personalized medical treatments. As conventional therapies like organ transplantation and synthetic drugs face limitations and risks, the demand for safer and more effective alternatives such as autologous cell therapy has surged. This shift aligns seamlessly with the paradigm of personalized medicine, tailoring treatments to an individual's genetic makeup, thus minimizing the risk of adverse reactions and maximizing treatment efficacy.

Additionally, the increasing prevalence of chronic and degenerative diseases, coupled with ongoing advancements in cell processing techniques and regulatory streamlining, further accelerates the autologous cell therapy market growth.

Autologous Cell Therapy Market Segment Insights

Autologous Cell Therapy Insights

The Market segmentation of Autologous Cell Therapy, based on therapy, includes Autologous Stem Cell Therapy, and Autologous Cellular Immunotherapies. The Autologous Stem Cell Therapy segment held the majority share in 2022 in the Autologous Cell Therapy Market revenue due to rising interest in personalized medical treatments. This innovative approach utilizes a patient's own stem cells to address a range of medical conditions, making it a promising facet of regenerative medicine.

Autologous Cell Application Insights

The global autologous cell application market segmentation, based on application, includes Cancer, cardiology, urology, neurovascular, gastrointestinal, general surgery, pain management & trauma. The cancer segment held the majority share in 2022 in the market revenue of Autologous Cell Therapy, which involves using a patient's own cells to combat cancer, has emerged as a promising approach within the realm of oncology. This treatment strategy has gained momentum due to its potential to provide highly personalized and effective solutions for various forms of cancer. According to the American Cancer Society, around 1.8 million new cases of cancer were identified in 2020, with cancer accounting for approximately 606,520 deaths in the US. The increasing consequences of a wide range of diseases across all age groups globally is driving the demand for drug discovery.

Autologous Cell Source Insights

The global autologous cell Source market segmentation, based on source, includes Bone Marrow, Epidermis, Others. The Bone Marrow segment held the majority share in 2022 in the Market revenue Autologous cell therapy, due to which Autologous cell therapy, specifically utilizing a patient's own bone marrow-derived cells, has emerged as a promising approach in regenerative medicine. This therapy's primary driver is its effectiveness in treating a wide range of conditions related to bone marrow dysfunction, such as blood disorders, leukemia, and certain types of cancer. 

As awareness of the limitations and potential risks of traditional treatments like allogeneic bone marrow transplants increases, both patients and healthcare providers are increasingly turning to autologous cell therapy as a safer and more tailored alternative. The therapy's success in treating these conditions, combined with ongoing advancements in cell processing techniques and supportive regulatory frameworks, is propelling the market growth of autologous cell therapy.

Autologous Cell Therapy End User Insights

The Market segments of Autologous Cell Therapy based on end user includes Hospitals & Clinics, Ambulatory Centers. The hospitals & Clinics segment dominated the market in 2022. hospitals & Clinics have become prominent hubs for the adoption and implementation of autologous cell therapy due to their central role in patient care and treatment. One of the primary drivers behind this growth is the increasing recognition among hospitals and clinics of the potential benefits of autologous cell therapy in offering highly personalized medical treatments. 

As awareness spreads among healthcare professionals and patients about the limitations and potential risks associated with traditional therapies, hospitals and clinics are increasingly integrating autologous cell therapy into their treatment options. This adoption is further facilitated by the development of specialized units and infrastructure for cell therapy within these institutions. The growing demand for these therapies, coupled with the establishment of streamlined protocols and collaborations with research institutions, is driving the market expansion of autologous cell therapy in the future.

Figure 2: Autologous Cell Therapy Market, By End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Autologous Cell Therapy Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Autologous Cell Therapy market is expected to account for USD 2.24 billion in 2022 and is expected to exhibit an 12.67 % CAGR during the study period. This is attributed to the region’s strong focus on research and development. North America has emerged as a hub for innovation in autologous cell therapy, with a robust ecosystem of pharmaceutical and biotechnology companies, academic institutions, and research centers dedicated to advancing this field. This drive is fueled by the region's commitment to finding cutting-edge medical solutions, particularly for challenging conditions like cancer, cardiovascular diseases, and neurological disorders, due to this fact North America as a leader in the market of autologous cell therapy.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: AUTOLOGOUS CELL THERAPY MARKET SHARE BY REGION 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Autologous Cell Therapy market is expected to account for the second-largest market share due to the presence of leading research institutes, hospitals, and medical centers that provide as a firm foundation for finding and developing novel medical and scientific therapies. The well-developed healthcare industry, as well as the prevalence of advanced healthcare infrastructure in economies such as the UK, Germany, Romania, France, and Portugal, are significant driving factors in the market. es. Further, the Germany market of Autologous Cell Therapy is expected to hold third place for the market share, and the UK market of Autologous Cell Therapy is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France market of Autologous Cell Therapy will hold the 5th place for the market share.

The Asia-Pacific Autologous Cell Therapy market is expected to grow at a high growth rate from 2023 to 2032. This is due to the increasing penetration of technological innovation in the R&D sector. The increased prevalence of chronic diseases in the region, such as cancer, stroke, heart disease, arthritis, multiple sclerosis, and others, is expected to drive the expansion of the market in the region. Moreover, China market of Autologous Cell Therapy is expected to hold the largest market share, and the India market of Autologous Cell Therapy is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the rest of the world market of Autologous Cell Therapy.

Autologous Cell Therapy Key Market Players & Competitive Insights

The leading players are investing a high amount of money in research and development activities to develop innovative products to enhance their product portfolios. They are also focusing on various strategic initiatives such as acquisitions and mergers, collaborations, partnerships, new product launches, and product expansions to strengthen their positions in the market.

One of the primary business strategies adopted by manufacturers in the global Autologous Cell Therapy industry to benefit clients and expand the market sector of Autologous Cell Therapy.

Aspen Neuroscience announced in August 2023 that the FDA had approved its Investigational New Drug (IND) application, allowing the company to begin a clinical trial for ANPD001, a personalised (autologous) cell therapy to treat Parkinson's disease by replacing lost dopamine neurons.

Moreover, Bristol Myers Squibb (US) Receives FDA Approval for New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts in August 2923. The Devens facility combines cutting-edge technology with top talent in the Boston area to propel the organisation into the next phase of its cell therapy journey.

Key Companies in the Autologous Cell Therapy Market includes.

• Bristol Myers Squibb (US)


• Bayer AG (Germany)


• Autolus Therapeutics (UK)


• Sangamo Therapeutics (US)


• Holostem Terapie Avanzate S.r.l.(Modena)


• Vericel Corporation (US)


• Opexa Therapeutics (US)


• BrainStorm Cell Therapeutics (US)


• Pharmicell Co., Inc. (South Korea)


• Daiichi Sankyo Co (Japan)., Ltd, among others

Autologous Cell Therapy Industry Developments

May 2020: Lonza (Switzerland) and Noga Therapeutics (Israel) Announced Collaboration to Develop Autologous Lentiviral Gene Therapy on the Cocoon Platform. The Cocoon® Platform is a closed, highly customizable, and scalable platform with few touchpoints that will aid Noga Therapeutics in the development of lentiviral gene therapies.

May 2022: Bluebird bio, Inc (US) announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. ZYNTEGLO is now for the first time marketed for sale.

Autologous Cell Therapy Market Segmentation

Autologous Cell Therapy Outlook

• Autologous Stem Cell Therapy


• Autologous Cellular Immunotherapies

Autologous Cell Therapy Application Outlook

• Cancer


• Cardiology


• Urology


• Neurovascular


• Gastrointestinal


• General Surgery


• Pain Management & Trauma

Autologous Cell Therapy Source Outlook

• Bone Marrow


• Epidermis


• Others

Autologous Cell Therapy End user Outlook

• Hospitals & Clinics


• Ambulatory Centers

Autologous Cell Therapy Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America